Oxford Immunotec Global PLC, a medical diagnostic company with U.S. headquarters in Marlborough, has raised $62.8 million through an initial public offering of stock that closed Monday.
The company, based in Oxford, England, sold 6.16 million shared of its stock at $12 per share, with the underwriters exercising in full their option to buy an additional 804,000 shares. The company’s stock price ended Monday at $15.75.
Oxford’s stock is trading on the NASDAQ Global market, under the ticker symbol OXFD.
The company, which is developing tests for infectious and immunological diseases, filed a registration statement Nov. 21 with the U.S. Securities and Exchanges Commission.
Oxford raised some $110 million through five rounds of equity financing between 2002 and mid-2012, with much of the proceeds going toward expanding sales and marketing for a tuberculosis diagnostic test.
Read more
UK Firm Expands To Marlborough | Awaits FDA approval for new TB test
Marlborough Lab Gets Federal TB Testing Contract
